The World Built an Ebola Vaccine for the Wrong Strain, and Congo Is Paying for It

On September 1, the World Health Organization issued emergency guidance on the one licensed Ebola vaccine in the world, and the guidance amounted to an admission of failure. The vaccine, Ervebo, may be used against the outbreak now killing people across the Democratic Republic of the Congo at a record pace, WHO said, but only inside a research trial — because nobody actually knows whether it works against the virus strain involved. That gap is not a fluke of bad timing. It is the predictable result of a global health system that spent the past decade building formidable defenses against exactly one species of a virus that has at least six, and is now relearning, at a cost of thousands of lives, that the last epidemic is a poor guide to the next one.

A Record-Breaking Outbreak, By the Numbers

The outbreak, caused by Bundibugyo ebolavirus, was declared a public health emergency of international concern on May 17, after the Congolese Ministry of Health confirmed the country's seventeenth recorded Ebola outbreak. By late August, according to WHO's official disease outbreak news bulletin, it had produced roughly 5,800 confirmed cases and more than 2,780 deaths across 60 health zones in six provinces of the DRC, with additional cases exported to Uganda and France — a case-fatality ratio above 48 percent. By September 1, the United Nations' emergency relief coordinator, Tom Fletcher, put the toll at 6,100 cases and 2,950 deaths, with more than 5,000 of those cases concentrated in Ituri province alone. It has already surpassed the DRC's 2018-2020 Ebola epidemic to become the deadliest in the country's history, and its growth curve is steeper than any prior outbreak of the virus on record.

Fletcher's office has released $57 million from the UN's Central Emergency Response Fund, against what he described as a $1.1 billion funding gap in the broader response. He was blunt about what closing that gap would take.

"We have the experience, the tools and extraordinary people risking their lives to stop this epidemic. What we need now is political will, access and resources."

A Vaccine Built for One Species, Not the Genus

The reason Ervebo cannot simply be deployed the way it was during the 2018-2020 outbreak is a matter of virology, not bureaucracy. Ebolavirus is a genus with several distinct species — Zaire, Sudan, Bundibugyo, Taï Forest and others — and Ervebo, developed and licensed after the 2014-2016 West African epidemic, targets only the Zaire species. As Doctors Without Borders has explained, the monoclonal antibody treatments that transformed survival rates in Zaire-virus outbreaks are similarly unapproved for Bundibugyo cases, leaving clinicians largely dependent on supportive care — fluids and oxygen — rather than the antivirals and antibody cocktails that cut mortality in the outbreaks the world had prepared for.

This was not an unforeseeable blind spot. In 2022, Sudan ebolavirus — a different, also-neglected species — caused an outbreak in Uganda that health officials at the time called a wake-up call precisely because no licensed vaccine or treatment existed for it either. Global health agencies, including CEPI and Gavi, outlined a plan to accelerate vaccine trials during that outbreak, which Uganda ultimately contained through contact tracing and isolation before a vaccine could even be deployed. Four years and one more warning later, WHO's own guidance on the current outbreak concludes that available evidence remains insufficient to determine whether Ervebo provides clinically meaningful protection against Bundibugyo virus, and recommends the vaccine be used only within research protocols — a ring-vaccination trial designed to generate, in the middle of the deadliest outbreak on record, the efficacy data that should have existed before it began.

Funding That Arrives After the Fire Starts

The pattern extends to money as much as to microbiology. WHO and the Africa Centres for Disease Control and Prevention announced a joint response plan in June seeking $518 million to fund six months of outbreak containment and cross-border preparedness — a plan launched only after the epidemic was already spreading across provincial and national borders. WHO Director-General Tedros Adhanom Ghebreyesus framed the appeal in reactive terms, saying the goal was to stop the outbreak where it stood, support countries already responding, and help neighboring countries detect and act quickly if cases appeared. That is a sound description of triage. It is not a description of preparedness. Mechanisms like the World Bank-housed Pandemic Fund exist to provide standing, pre-committed resources precisely so that outbreak response does not depend on emergency appeals issued after transmission chains have already multiplied — but relief here has again followed the outbreak rather than preceding it.

• Confirmed cases by late August: roughly 5,800, including exported cases in Uganda and France
• Deaths as of September 1: 2,950, a case-fatality ratio above 48 percent
• Funding gap cited by the UN's emergency relief coordinator: $1.1 billion
• Months between the 2022 Sudan-virus "wake-up call" in Uganda and this outbreak: roughly 44

The Case for Restraint — and Why It Falls Short Here

There is a genuine argument against building vaccine stockpiles for every rare pathogen species: global health budgets are finite, competing demands from malaria, tuberculosis and childhood immunization are far larger in aggregate disease burden, and Ebola species other than Zaire have historically produced smaller, more containable outbreaks that basic public health measures — isolation, contact tracing, safe burials — have controlled without any vaccine at all, including the 2022 Sudan-virus outbreak in Uganda. Spending hundreds of millions of dollars on multivalent vaccine platforms against pathogens that might cause a few hundred cases a decade is a defensible target for skepticism, and no health minister has an unlimited budget to hedge against every risk.

That argument was more persuasive before this outbreak than it is now. The premise that non-Zaire Ebola species produce small, self-limiting outbreaks has been undercut by the numbers coming out of Ituri province, where a fatality rate near 50 percent has now been sustained across thousands of confirmed cases. And the marginal cost of validating cross-protection for existing vaccine platforms — work that, per WHO's own guidance, remains technically within reach through combined animal and immunological data — is a rounding error next to the pandemic-preparedness budgets governments committed after COVID-19, and a rounding error next to the $1.1 billion now being raised, weeks into the outbreak, to fight a fire that better-timed research funding might have helped keep from spreading this far.

The fix is not exotic. Bodies like CEPI and the Pandemic Fund should be pressed to maintain active development and stockpiling programs against major Ebolavirus species with epidemic potential, not only the one that caused the last headline-grabbing epidemic. Funding appeals for in-progress outbreaks will always be necessary, but they should supplement standing preparedness investment, not substitute for it. The 2022 Sudan-virus outbreak in Uganda was treated as an anomaly to be managed rather than a signal to be acted on. The Bundibugyo outbreak now killing more people in the Congo than any Ebola epidemic in that country's history is the cost of having drawn that lesson too narrowly the first time. The next outbreak, of whichever species emerges next, will test whether the lesson has finally been learned.